<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00334763</url>
  </required_header>
  <id_info>
    <org_study_id>NU 05L1</org_study_id>
    <secondary_id>NU-05L1</secondary_id>
    <secondary_id>NU-1362-038</secondary_id>
    <secondary_id>GENENTECH-AVF3646s</secondary_id>
    <nct_id>NCT00334763</nct_id>
  </id_info>
  <brief_title>Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study of Radiation Followed by Paclitaxel, Carboplatin, and Bevacizumab (PCA) in Patients With Stage IIIB and IV Squamous Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth&#xD;
      of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal&#xD;
      antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the&#xD;
      ability of tumor cells to grow and spread. Others find tumor cells and help kill them or&#xD;
      carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells&#xD;
      by blocking blood flow to the tumor. Giving radiation therapy together with chemotherapy and&#xD;
      monoclonal antibody therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving radiation therapy together with&#xD;
      chemotherapy and bevacizumab works in treating patients with recurrent, unresectable or stage&#xD;
      III or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate reduction in toxicity, in terms of pulmonary hemorrhage, in patients with&#xD;
           recurrent, unresectable or stage IIIB or IV squamous non-small cell lung cancer treated&#xD;
           with radiotherapy followed by paclitaxel, carboplatin, and bevacizumab.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall and progression-free survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: Patients undergo radiotherapy to the primary tumor, clinically involved lymph nodes,&#xD;
      and any other disease-causing symptoms or bronchial compression once daily, 5 days a week,&#xD;
      for 2 weeks in weeks 1 and 2. Beginning in week 4, patients receive paclitaxel IV over 3&#xD;
      hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1.&#xD;
      Treatment with paclitaxel, carboplatin, and bevacizumab repeats every 3 weeks for 4 courses&#xD;
      in the absence of unacceptable toxicity. Patients achieving complete response, partial&#xD;
      response, or stable disease after 4 courses receive bevacizumab alone as above in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 32 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal Investigator felt risk to patients was too high.&#xD;
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in toxicity measured by pulmonary hemorrhage rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival by Kaplan-Meier</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemoprotection</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Predominantly squamous cell histology&#xD;
&#xD;
               -  Cytologic or histologic elements can be established on metastatic tumor aspirates&#xD;
                  or biopsy&#xD;
&#xD;
          -  Advanced disease, meeting 1 of the following staging criteria:&#xD;
&#xD;
               -  Stage IIIB disease with malignant pleural effusion&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
               -  Recurrent, unresectable disease&#xD;
&#xD;
          -  Measurable or nonmeasurable disease&#xD;
&#xD;
          -  No extrathoracic only disease&#xD;
&#xD;
          -  No known CNS metastases by head CT scan with contrast or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Transaminases &lt; 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine clearance ≥ 45 mL/min&#xD;
&#xD;
          -  Urine protein:creatinine ratio ≤ 1.0 by spot urinalysis&#xD;
&#xD;
          -  INR &lt; 1.5 ULN&#xD;
&#xD;
          -  PTT normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients use effective contraception&#xD;
&#xD;
          -  No serious nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No ongoing fever&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No stroke within the past 6 months&#xD;
&#xD;
          -  No history of hypertension unless well-controlled (i.e., blood pressure &lt; 150/100 mmHg&#xD;
             on a stable regimen of antihypertensive therapy)&#xD;
&#xD;
          -  No New York Heart Association grade III or IV congestive heart failure&#xD;
&#xD;
          -  No serious cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No peripheral vascular disease ≥ grade 2&#xD;
&#xD;
          -  No other clinically significant cardiovascular disease&#xD;
&#xD;
          -  No abdominal fistula&#xD;
&#xD;
          -  No gastrointestinal perforation&#xD;
&#xD;
          -  No intra-abdominal abscess within the past 6 months&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other malignancy curatively treated within the past 5 years&#xD;
&#xD;
          -  No history of thrombotic or hemorrhagic disorders&#xD;
&#xD;
          -  No gross hemoptysis (i.e., red blood ≥ ½ teaspoon) within the past 3 months&#xD;
&#xD;
          -  No bleeding requiring intervention or ≥ grade 2&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No prior systemic chemotherapy for metastatic NSCLC&#xD;
&#xD;
          -  More than 6 months since prior adjuvant chemotherapy for early stage (i.e., stage&#xD;
             IB-IIIA) NSCLC&#xD;
&#xD;
          -  More than 3 weeks since prior immunotherapy, hormonal therapy, or radiotherapy&#xD;
&#xD;
          -  More than 28 days since prior and no concurrent major surgery&#xD;
&#xD;
          -  More than 7 days since prior minor surgery, fine-needle aspiration, or core biopsy&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent participation in another experimental&#xD;
             drug study&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation&#xD;
&#xD;
               -  Concurrent prophylactic anticoagulation of venous access device allowed&#xD;
&#xD;
          -  No concurrent chronic treatment with aspirin (&gt; 325 mg/day) or nonsteroidal&#xD;
             anti-inflammatory drugs known to inhibit platelet function&#xD;
&#xD;
          -  No concurrent dipyridamole, ticlopidine, clopidogrel, or cilostazol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyoti D. Patel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Northwestern Healthcare - Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>June 7, 2006</study_first_submitted>
  <study_first_submitted_qc>June 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2006</study_first_posted>
  <last_update_submitted>July 9, 2012</last_update_submitted>
  <last_update_submitted_qc>July 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <name_title>Jyoti D. Patel</name_title>
    <organization>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</organization>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

